BUZZ-BridgeBio rises after $550 mln convertible debt offering

Reuters01-16
BUZZ-BridgeBio rises after $550 mln convertible debt offering

** BridgeBio Pharma BBIO.O shares up 0.5% at $76.63 early Fri after co secures capital raise

** Genetic diseases-focused biopharma early Fri announced pricing private offering of $550 mln 0.75% 7-yr convertible bonds (CBs)

** Initial conversion price of $110.58 set 45% above stock's last close of $76.26

** BBIO fell 2% on Thurs after co unveiled the offering late Weds to prefund the repayment of its $550 mln principal 2.5% CBs due 2027, and for general corp purposes

** Co also plans to use up to $82.5 mln of cash on hand to repurchase stock from the new CB purchasers to facilitate hedging transactions

** Palo Alto, California-based co has about $15 bln market cap

** With the move on the session, stock up 125% over the past 12 months and hit record intraday high of $79.88 on Tues

** All 20 analysts are bullish, including 6 "strong buy" ratings; median PT $86, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment